Impact Biomedical (IBO) Free Cash Flow (2022 - 2026)
Impact Biomedical's (IBO) quarterly Free Cash Flow came in at -$464000.0 in Q1 2026, up 31.96% YoY from -$351608.9 in Q1 2025, and down 568.69% on a QoQ basis from $99000.0 in Q4 2025.
Impact Biomedical (IBO) Free Cash Flow (2022 - 2026) Analysis & Trends
Impact Biomedical (IBO) has 5 years of Free Cash Flow data on file, last reported at -$464000.0 in Q1 2026.
- Quarterly Free Cash Flow rose 31.96% year-over-year to -$464000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.7 million (up 45.25% YoY) and the FY2025 annual result came in at -$1.9 million, up 33.78% from the prior year.
- Free Cash Flow fell to -$464000.0 in Q1 2026, from $99000.0 in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of $99000.0 in Q4 2025 to a low of -$1.0 million in Q1 2023.
- A 5-year average of -$616133.3 and a median of -$672000.0 in 2023 frame the typical range for Free Cash Flow.
- Annual changes were most pronounced in 2024 — Free Cash Flow plunged 127.71% — and 2025, when it soared 110.04%.
- Tracing IBO's Free Cash Flow over 5 years: stood at -$363000.0 in 2022, then declined by 19.28% to -$433000.0 in 2023, then sank by 127.71% to -$986000.0 in 2024, then soared by 110.04% to $99000.0 in 2025, then tumbled by 568.69% to -$464000.0 in 2026.
- The last three Free Cash Flow figures came in at -$464000.0 (Q1 2026), $99000.0 (Q4 2025), and -$613000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | Impact Biomedical | 49.54 Mn | 49.53 Mn | 2,000.00 | 470,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 470,000.00 |
| Jun 30, 2026 | 470,000.00 |
| Mar 31, 2026 | -464,000.00 |
| Mar 31, 2026 | -464,000.00 |
| Dec 31, 2025 | 99,000.00 |
| Dec 31, 2025 | 99,000.00 |
| Sep 30, 2025 | -613,000.00 |
| Sep 30, 2025 | -613,000.00 |
| Jun 30, 2025 | -694,000.00 |
| Jun 30, 2025 | -694,000.00 |
| Mar 31, 2025 | -682,000.00 |
| Mar 31, 2025 | -682,000.00 |
| Dec 31, 2024 | -986,000.00 |
| Dec 31, 2024 | -986,000.00 |
| Sep 30, 2024 | -1.00 Mn |
| Sep 30, 2024 | -1.00 Mn |
| Jun 30, 2024 | -385,000.00 |
| Jun 30, 2024 | -385,000.00 |
| Mar 31, 2024 | -482,000.00 |
| Mar 31, 2024 | -482,000.00 |